ArticleDiscover oncology2026
A multi-scale feature fusion of deep learning network for classifying acute leukemia genetic subtypes from blood smear images.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- XHIC-Net: An Explainable Hybrid Involution-Convolution Network for Blood Smear Cell Morphology Classification.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Acute leukemia (AL) is a common type of hematological malignancy. Accurate classification of its genetic subtypes is crucial for achieving precise clinical diagnosis and treatment. However, some genetic subtypes lack distinct morphological features and can easily be confused with other AL types. Additionally, genetic subtypes often relies on expensive genetic testing equipment. These factors limit the ability to achieve precise diagnosis of AL in clinical settings. To tackle this clinical challenge, we developed the EMAResDrop model by enhancing pre-trained ResNet50 with DropBlock and Efficient Multi-Scale Attention (EMA) techniques to improve the classification accuracy of genetic subtypes of AL. Our model was evaluated on two AL datasets comprising blood smear images from 469 cases of acute lymphoblastic leukemia (ALL) and 269 cases of acute myeloid leukemia (AML) patients. In the test set for ALL, the EMAResDrop model effectively distinguished between BCR::ABL1, TCF3::PBX1, KMT2A rearrangement, ETV6::RUNX1, and ALL-Others, achieving accuracies of 0.967 ± 0.005, 0.954 ± 0.006, 0.946 ± 0.005, 0.981 ± 0.006, and 0.929 ± 0.002, respectively. Additionally, the classification accuracies for different AML subtypes were 0.992 ± 0.013 for PML::RARA, 0.929 ± 0.004 for RUNX1::RUNX1T1, and 0.926 ± 0.005 for CBFB::MYH11. When compared with four benchmark models (VGG16, InceptionV3, DenseNet121, and ResNet50), EMAResDrop exhibited superior performance, achieving classification accuracies of 0.954 ± 0.015 and 0.949 ± 0.003 for the ALL and AML datasets, respectively. The external test results further confirmed the strong generalization ability of the model. Overall, this study enhanced the genotyping diagnosis of AL and has the potential to improve early diagnosis and treatment, potentially supporting more effective clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.